After $152bn In Deals Could Allergan CEO Saunders Double His Money?
This article was originally published in Scrip
Executive Summary
Allergan plc CEO Brent Saunders traded up from the $8.7bn sale of Bausch & Lomb Inc. in 2013 to the $66bn merger of Allergan and Actavis plc earlier this year as the companies he helmed were acquired or made their own big buys, bringing the dealmaker's two-year transaction total to $152bn, and now Saunders could double that number if Pfizer Inc. proposes a suitable acquisition price for Allergan.
You may also be interested in...
Amgen Hands Omecamtiv Back To Cytokinetics
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Finance Watch: Olema IPO Raises $209m To Advance OPI-1250 For Breast Cancer
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
Imago Raises $80m Series C To Take Bomedemstat Into Phase III
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.
Need a specific report? 1000+ reports available
Buy Reports